Abstract
Nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer and this effect is mediated in part through inhibition of type 2 prostaglandin endoperoxide synthase/cyclo-oxygenase (COX-2). In the present study, we demonstrate that COX-2 expression and PGE2 synthesis are up-regulated by an IGF-II/IGF-I receptor autocrine pathway in Caco-2 colon carcinoma cells. COX-2 mRNA and PGE2 levels are higher in proliferating cells compared with post-confluent differentiated cells and in cells that constitutively overexpress IGF-II. Up-regulation of COX-2 expression by IGF-II is mediated through activation of IGF-I receptor because: (i) treatment of Caco-2 cells with a blocking antibody to the IGF-I receptor inhibits COX-2 mRNA expression; (ii) transfection of Caco-2 cells with a dominant negative IGF-I receptor reduces COX-2 expression and activity. Also, the blockade of the PI3-kinase, that mediates the proliferative effect of IGF-I receptor in Caco-2 cells, inhibits IGF-II-dependent COX-2 up-regulation and PGE2 synthesis. Moreover, COX-2 expression and activity inversely correlate with the increase of apoptosis in parental, IGF-II and dominant-negative IGF-I receptor transfected cells. This study suggests that induction of proliferation and tumor progression of colon cancer cells by the IGF-II/IGF-I receptor pathway may depend on the activation of COX-2-related events.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- IGF-II:
-
insulin-like growth factor-II
- IGF-Ir:
-
IGF-I receptor
- dnIGF-Ir:
-
dominant negative IGF-I receptor
- COX:
-
cyclo-oxygenase
- PG:
-
prostaglandin
- NSAIDs:
-
nonsteroidal anti-inflammatory drugs
- RT–PCR:
-
reverse transcription polymerase chain reaction
- MAPK-kinase:
-
mitogen-activated protein kinase-kinase
- PI3-kinase:
-
phosphatidylinositol 3-kinase
References
Barry OP, Kazanietz MG, Praticò D and FitzGerald GA. . 1999 J. Biol. Chem. 274: 7545–7556.
Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL and Morrow JD. . 1997 Proc. Natl. Acad. Sci. USA 94: 657–662.
DuBois RN, Awad J, Morrow J, Roberts RJ II and Bishop PR. . 1994 J. Clin. Invest. 93: 493–498.
Dufourny B, Alblas J, van Teeffelen HAAM, van Schaik FMA, van der Burg B, Steenbergh PH and Sussenbach JS. . 1997 J. Biol. Chem. 272: 31163–31171.
Eberhart CE and DuBois RN. . 1995 Gastroenterology 109: 285–301.
Flier JS, Usher P and Moses AC. . 1986 Proc. Natl. Acad. Sci. USA 83: 664–668.
Garrouste FL, Remacle-Bonnet MM, Lehman MM-A, Marvaldi JM and Pommier GJ. . 1997 Endocrinology 138: 2021–2032.
Guo Y-S, Narayan S, Chandrasekhar Y and Singh P. . 1992 Gastroenterology 102: 1101–1108.
Humbel RE. . 1990 Eur. J. Biochem. 190: 445–462.
Kamitani H, Geller M and Eling T. . 1998 J. Biol. Chem. 273: 21569–21577.
Kato H, Faria TN, Stannard B, Roberts CT and LeRoith D. . 1993 J. Biol. Chem. 268: 2655–2661.
Kinzler KW and Vogelstein B. . 1996 Cell 87: 159–170.
Kojima M, Morisaki T, Izuhara K, Uchiyama A, Matsunari Y, Katano M and Tanaka M. . 2000 Oncogene 19: 1225–1231.
Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL and Prescott SM. . 1996 Proc. Natl. Acad. Sci. USA 93: 4816–4820.
Nardone G, Romano M, Calabrò A, Pedone PV, De Sio I, Persico M, Budillon G, Bruni CB, Riccio A and Zarrilli R. . 1996 Hepatology 23: 1304–1312.
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM. . 1996 Cell 87: 803–809.
Pignata S, Maggini L, Zarrilli R, Rea A and Acquaviva AM. . 1994 Cell Growth Differ. 5: 967–973.
Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assman P, Haffen K, Fogh J and Zwelbaum A. . 1983 Biol. Cell. 47: 323–330.
Plummer SM, Holloway KA, Manson MM, Munks RJL, Kaptein A, Farrow S and Howells L. . 1999 Oncogene 18: 6013–6020.
Pommier GJ, Garrouste FL, El Atiq F, Roccabianca M, Marvaldi JL and Remacle-Bonnet MM. . 1992 Cancer Res. 52: 3182–3188.
Podolsky DK. . 1993 Am. J. Physiol. 264: G179–G186.
Prescott SM and Fitzpatrick FA. . 2000 Biochim. Biophys. Acta 1470: M69–M78.
Remacle-Bonnet MM, Garrouste FL, Heller S, Andrè F, Marvaldi JL and Pommier GJ. . 2000 Cancer Res. 60: 2007–2017.
Ricchi P, Pignata S, Di Popolo A, Memoli AM, Apicella A, Zarrilli R and Acquaviva AM. . 1997 Int. J. Cancer 73: 880–884.
Romano M, Ricci V, Memoli A, Tuccillo C, Di Popolo A, Sommi P, Acquaviva AM, Del Vecchio Blanco C, Bruni CB and Zarrilli R. . 1998 J. Biol. Chem. 273: 28560–28563.
Romashkova JA and Makarov SS. . 1999 Nature 401: 86–90.
Rubin R and Baserga R. . 1995 Lab. Invest. 73: 311–331.
Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN. . 1998 Cancer Res. 58: 362–366.
Simon TC and Gordon JI. . 1995 Curr. Opin. Gen. Dev. 5: 577–586.
Singh P and Rubin N. . 1993 Gastroenterology 105: 1218–1237.
Tsujii M and DuBois RN. . 1995 Cell 83: 493–501.
Tsujii M, Sunao K and DuBois RN. . 1997 Proc. Natl. Acad. Sci. USA 94: 3336–3340.
Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M and DuBois RN. . 1998 Cell 93: 705–716.
Williams CS and DuBois RN. . 1996 Am. J. Physiol. 270: G393–G400.
Williams CS, Smalley W and DuBois RN. . 1997 J. Clin. Invest. 100: 1325–1329.
Zarrilli R, Pignata S, Romano M, Gravina A, Casola S, Bruni CB and Acquaviva AM. . 1994 Cell Growth Differ. 5: 1085–1091.
Zarrilli R, Romano M, Pignata S, Casola S, Bruni CB and Acquaviva AM. . 1996 J. Biol. Chem. 271: 8108–8114.
Zarrilli R, Pignata S, Apicella A, Di Popolo A, Memoli A, Ricchi P, Salzano S and Acquaviva AM. . 1999a Gastroenterology 116: 1358–1366.
Zarrilli R, Tuccillo C, Santangelo M, Nardone G and Romano M. . 1999b Am. J. Gastroenterol. 94: 3376–3378.
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW. . 1997 Science 276: 1268–1272.
Acknowledgements
We thank Dr D LeRoith (NIH, Bethesda, MD, USA) for kindly providing the dnIGF-Ir vector, Drs D Zanzi and G Ruggiero for help in FACS analysis, and Dr M Romano for critical reading of the manuscript. We also thank M Berardone for the artwork and R Cerillo for technical support. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) and Ministero dell'Università per la Ricerca Scientifica e Tecnologica (MURST). Dr A Apicella was recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Di Popolo, A., Memoli, A., Apicella, A. et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19, 5517–5524 (2000). https://doi.org/10.1038/sj.onc.1203952
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203952
Keywords
This article is cited by
-
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Cellular and Molecular Life Sciences (2022)
-
Traitement adjuvant du cancer colorectal : l’aspirine, une biothérapie ciblée ?
Oncologie (2014)
-
ω-3 Polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis
Phytochemistry Reviews (2014)
-
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells
BMC Cancer (2011)
-
PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac
Tumor Biology (2010)